Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Exclusion Criteria

• •Patients with no advanced breast cancer.
• •Breast cancer patients with tumors HER 2-negative.
• •The patient has another active malignancy other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear\> 5 years without evidence of disease could be included.
• •The patient has uncontrolled brain metastases.
• •Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.
• •Known hypersensitivity to trastuzumab or to any of its components.
• •Patients with severe dyspnea at rest or requiring supplemental oxygen.
• •Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction on ECG or hypertension poorly controlled.
• •Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).
• •The patient is pregnant or lactating. Women of childbearing potential should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.